Advertisement

Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults

      Background

      The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by the U.S. Food and Drug Administration for adults, but its role in older adults is unclear.

      Purpose

      To compare PCV13 strategies to currently recommended vaccination strategies in adults aged ≥65 years.

      Methods

      Using a Markov model, the cost effectiveness of PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), alone or in combination, was estimated, in adults aged either 65 years or 75 years. No prior vaccination, prior vaccination, and vaccine hyporesponsiveness scenarios were examined. Pneumococcal disease rates, indirect childhood PCV13 effects, and costs were estimated using CDC Active Bacterial Core surveillance data and U.S. national databases. An expert panel estimated vaccine-related protection. A societal perspective was taken and outcomes were discounted 3% per year.

      Results

      In those aged 65 years, single-dose PCV13 cost $11,300 per quality-adjusted life-year (QALY) gained compared to no vaccination; at ages 65 and 80 years, PCV13 cost $83,000/QALY. In those aged 75 years, single-dose PCV13 cost $62,800/QALY gained. PPSV23 cost more and was less effective than PCV13. Results were sensitive to varying vaccine effectiveness and indirect effect estimates. In hyporesponsiveness scenarios, cost-effectiveness ratios increased by 37%–78% for single-dose strategies and 29%–35% for multiple-dose strategies.

      Conclusions

      Single-dose PCV13 strategies are likely to be economically reasonable in older adults.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • CDC
        2012 pink book, pneumococcal disease.
        • CDC
        Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 1997; 46: 1-24
        • CDC
        Epidemiology and prevention of vaccine-preventable diseases.
        8th ed. Public Health Foundation, Washington DC2004
        • CDC
        Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
        MMWR Morb Mortal Wkly Rep. 2010; 59: 1102-1106
        • Fedson D.
        • Musher D.
        Pneumococcal polysaccharide vaccine.
        in: Plotkin S.A. Orenstein W.A. Vaccines. 4th ed. Saunders, Philadelphia2004
        • Huss A.
        • Scott P.
        • Stuck A.E.
        • Trotter C.
        • Egger M.
        Efficacy of pneumococcal vaccination in adults: a meta-analysis.
        CMAJ. 2009; 180: 48-58
        • Moberley S.A.
        • Holden J.
        • Tatham D.P.
        • Andrews R.M.
        Vaccines for preventing pneumococcal infection in adults.
        Cochrane Database Syst Rev. 2008; (CD000422)
        • Hak E.
        • Grobbee D.E.
        • Sanders E.A.
        • et al.
        Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
        Neth J Med. 2008; 66: 378-383
        • Ahmed F.
        • Temte J.L.
        • Campos-Outcalt D.
        • Schunemann H.J.
        Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S.
        CDC. Vaccine. 2011; 29: 9171-9176
        • Black S.B.
        • Shinefield H.R.
        • Ling S.
        • et al.
        Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
        Pediatr Infect Dis J. 2002; 21: 810-815
        • Hammitt L.L.
        • Bulkow L.R.
        • Singleton R.J.
        • et al.
        Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
        Vaccine. 2011; 29: 2287-2295
        • Lexau C.A.
        • Lynfield R.
        • Danila R.
        • et al.
        Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
        JAMA. 2005; 294: 2043-2051
        • Pilishvili T.
        • Lexau C.
        • Farley M.M.
        • et al.
        Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
        J Infect Dis. 2010; 201: 32-41
        • CDC
        Adult vaccination coverage—U.S.,2010.
        MMWR Morb Mortal Wkly Rep. 2012; 61: 66-72
        • Smith K.J.
        • Wateska A.R.
        • Nowalk M.P.
        • Raymund M.
        • Nuorti J.P.
        • Zimmerman R.K.
        Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
        JAMA. 2012; 307: 804-812
        • Smith K.J.
        • Zimmerman R.K.
        • Lin C.J.
        • et al.
        Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.
        Vaccine. 2008; 26: 1420-1431
        • Arias E.
        U.S. life tables, 2006.
        National Center for Health Statistics, Hyattsville MD2010
      1. Gold M.R. Siegel J.E. Russell L.B. Weinstein M.C. Cost-effectiveness in health and medicine. Oxford University Press, New York1996
        • Fry A.M.
        • Zell E.R.
        • Schuchat A.
        • Butler J.C.
        • Whitney C.G.
        Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.
        Vaccine. 2002; 21: 303-311
        • American Lung Association
        Trends in pneumonia and influenza morbidity and mortality.
        (2010)
        • Grijalva C.G.
        • Nuorti J.P.
        • Arbogast P.G.
        • Martin S.W.
        • Edwards K.M.
        • Griffin M.R.
        Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U.S.: a time-series analysis.
        Lancet. 2007; 369: 1179-1186
        • Rubin J.L.
        • McGarry L.J.
        • Strutton D.R.
        • et al.
        Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S.
        Vaccine. 2010; 28: 7634-7643
        • Weycker D.
        • Strutton D.
        • Edelsberg J.
        • Sato R.
        • Jackson L.A.
        Clinical and economic burden of pneumococcal disease in older U.S. adults.
        Vaccine. 2010; 28: 4955-4960
        • Wroe P.C.
        • Finkelstein J.A.
        • Ray G.T.
        • et al.
        Aging population and future burden of pneumococcal pneumonia in the U.S.
        J Infect Dis. 2012; 205: 1589-1592
        • Jackson L.A.
        • Benson P.
        • Sneller V.P.
        • et al.
        Safety of revaccination with pneumococcal polysaccharide vaccine.
        JAMA. 1999; 281: 243-248
        • Sisk J.E.
        • Whang W.
        • Butler J.C.
        • Sneller V.P.
        • Whitney C.G.
        Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
        Ann Intern Med. 2003; 138: 960-968
        • Centers for Medicare & Medicaid Services
        Physician Fee Schedule Search (CPT 90471; Data Year: 2006).
        • CDC
        CDC Vaccine Price List.
        • Cantor S.B.
        Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment.
        Med Decis Making. 1994; 14: 259-265
        • Braithwaite R.S.
        • Meltzer D.O.
        • King Jr, J.T.
        • Leslie D.
        • Roberts M.S.
        What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?.
        Med Care. 2008; 46: 349-356
        • Laupacis A.
        • Feeny D.
        • Detsky A.S.
        • Tugwell P.X.
        How attractive does a new technology have to be to warrant adoption and utilization?.
        CMAJ. 1992; 146: 473-481
        • U.S. Census Bureau
        National Population Estimates for the 2000s.
        • Millar E.V.
        • Watt J.P.
        • Bronsdon M.A.
        • et al.
        Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
        Clin Infect Dis. 2008; 47: 989-996
        • Hansen J.
        • Black S.
        • Shinefield H.
        • et al.
        Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs.
        Pediatr Infect Dis J. 2006; 25: 779-781
      2. (ClinicalTrials.gov website)
        Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA).
        • Zielen S.
        • Buhring I.
        • Strnad N.
        • Reichenbach J.
        • Hofmann D.
        Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.
        Infect Immun. 2000; 68: 1435-1440
        • Jackson L.A.
        • Neuzil K.M.
        • Nahm M.H.
        • et al.
        Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
        Vaccine. 2007; 25: 4029-4037
        • Musher D.M.
        • Manof S.B.
        • Liss C.
        • et al.
        Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
        J Infect Dis. 2010; 201: 516-524
        • Goldblatt D.
        • Southern J.
        • Andrews N.
        • et al.
        The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
        Clin Infect Dis. 2009; 49: 1318-1325
        • Smith K.J.
        • Zimmerman R.K.
        • Nowalk M.P.
        • Roberts M.S.
        Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis.
        Vaccine. 2009; 27: 3159-3164
        • Huang S.S.
        • Johnson K.M.
        • Ray G.T.
        • et al.
        Healthcare utilization and cost of pneumococcal disease in the U.S..
        Vaccine. 2011; 29: 3398-3412